ALX Oncology Holdings Inc - ESG Rating & Company Profile powered by AI
This SDG rating for ALX Oncology Holdings Inc represents its reporting of the United Nations SDGs. Browse to the end of this page for potential risks for ALX Oncology Holdings Inc based on sector, geography and size. If you are employed by ALX Oncology Holdings Inc and you wish to use your Sustainability rating, please get in touch.
ALX Oncology Holdings Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.3; made up of an environmental score of 1.3, social score of 0.0 and governance score of 2.7.
1.3
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1747 | Sinphar Pharmaceutical Co Ltd | 1.4 | Low |
| 1747 | WooGene B&G Co Ltd | 1.4 | Low |
| 1755 | ALX Oncology Holdings Inc | 1.3 | Low |
| 1755 | Cheng Du Sheng Nuo Biotec Co Ltd | 1.3 | Low |
| 1755 | Alimera Sciences Inc | 1.3 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does ALX Oncology Holdings Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes ALX Oncology Holdings Inc report the average age of the workforce?
Sign up for free to unlockDoes ALX Oncology Holdings Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose cybersecurity risks?
Sign up for free to unlockDoes ALX Oncology Holdings Inc offer flexible work?
Sign up for free to unlockDoes ALX Oncology Holdings Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes ALX Oncology Holdings Inc conduct supply chain audits?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes ALX Oncology Holdings Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose water use targets?
Sign up for free to unlockDoes ALX Oncology Holdings Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid ALX Oncology Holdings Inc have a product recall in the last two years?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose incidents of discrimination?
Sign up for free to unlockDoes ALX Oncology Holdings Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas ALX Oncology Holdings Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose parental leave metrics?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes ALX Oncology Holdings Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes ALX Oncology Holdings Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs ALX Oncology Holdings Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose its waste policy?
Sign up for free to unlockDoes ALX Oncology Holdings Inc report according to TCFD requirements?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose energy use targets?
Sign up for free to unlockDoes ALX Oncology Holdings Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes ALX Oncology Holdings Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for ALX Oncology Holdings Inc
These potential risks are based on the size, segment and geographies of the company.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.